Avalo Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $59 | $0 |
Gross Profit | -17 | 59 | -9,990 | |
EBITDA | -36,306 | -19,601 | -13,574 | -30,555 |
EBIT | -36,340 | -19,618 | -13,590 | -30,614 |
Net Income | -36,358 | -19,630 | -13,720 | -30,625 |
Net Change In Cash | 0 | 0 | 59 | 0 |
Free Cash Flow | -18,076 | -17,691 | -14,246 | -16,365 |
Cash | 85,382 | 24,988 | 15,858 | 26,963 |
Basic Shares | 43,602 | 20,106 | 18,512 | 14,000 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $59 | $441 | $1,924 | $18,051 |
Gross Profit | 59 | 807 | 640 | 14,617 |
EBITDA | -77,750 | -34,846 | -23,286 | -37,294 |
EBIT | -78,094 | -35,015 | -23,444 | -37,460 |
Net Income | -78,259 | -35,129 | -31,544 | -41,658 |
Net Change In Cash | 59 | 441 | 1,924 | 18,051 |
Free Cash Flow | -51,458 | -49,056 | -30,838 | -26,846 |
Cash | 15,858 | 134,546 | 7,415 | 13,172 |
Basic Shares | 13,404 | 10,784 | 277 | 39 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.83 |
2026-03-31 | -$0.98 |
2025-12-31 | -$0.37 |
2025-09-30 | -$2.19 |